AI tool successfully predicts outcomes of immunotherapy in lung cancer
· Medical Xpressby University of Chicago Medical Center
edited by Gaby Clark, reviewed by Robert Egan
Gaby Clark
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Artificial intelligence (AI) tools can help physicians predict treatment and survival outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy, according to a new study published in Nature Medicine. The study reported findings from the I3LUNG project, a large international trial aimed at improving the treatment of metastatic NSCLC by developing AI-based predictive models that can help determine the best therapeutic approach for each individual.
Immunotherapy—a cancer treatment that boosts and uses the power of the patient's immune system against cancer cells—has transformed lung cancer treatment, achieving long-term benefit in 20% to 30% of patients. However, most patients experience resistance to treatment, and physicians still cannot reliably predict which patients will benefit from immunotherapy. Today, treatment decisions rely heavily on the expression of PD-L1—a biomarker with well-known limitations.
"We need smarter tools," said thoracic oncologist Marina Garassino, MD, professor of medicine at UChicago Medicine and senior author of the study.
Better predictive biomarkers could identify which patients are likely to respond to immunotherapy at diagnosis, avoiding unnecessary toxicity and cost. Improving the ability to make these predictions can help physicians better tailor treatments for individual patients. The I3LUNG project set out to develop and validate AI tools to support immunotherapy decisions in advanced NSCLC.
Building models from diverse patient data
For the study, the international research team enrolled 2,396 patients with advanced NSCLC treated with immunotherapy across six centers in Italy, Germany, Greece, Israel, Spain and the United States. For the first phase of the project, the team integrated multiple types of data, including clinical, imaging, pathology and genomic data, from each patient into a database. They then built and tested two families of AI models trained to predict treatment response and survival using all the collected data.
The researchers found that their AI models consistently outperformed all standard clinical biomarkers. Area under the curve, or AUC, is a machine learning metric that quantifies how well an AI model classifies information correctly or, in this case, predicts survival outcomes accurately. Scores between 0.8 and 0.9 are considered "excellent." In the I3LUNG study, the AI model that used clinical and blood data achieved an AUC score of 0.77, while the model that incorporated clinical and blood data along with imaging and digital pathology achieved an AUC score of 0.88.
When doctors used the tool
Part of the study tested what happens when humans collaborate with the AI tools. Twenty physicians—10 lung cancer experts and 10 from other specialties—reviewed 100 real patient cases, first without and then with AI support. Access to the AI tool improved sensitivity for identifying responders, with AUC rising from 0.72 to 0.87.
Physicians who were not lung cancer experts showed the greatest improvements, a finding with direct relevance to community oncology settings where thoracic expertise may be limited. Interphysician agreement rose from slight to moderate, suggesting the tool also promotes more consistent clinical reasoning across different levels of experience.
"This alignment between machine and clinical logic is essential for building trust in AI-assisted decision-making," Garassino said.
Next phase shifts to treatment decisions
The study reported the project's retrospective phase. I3LUNG is now prospectively enrolling more than 2,000 patients across the same six international centers, allowing the researchers to focus on treatment optimization. They said this dimension is important because AI model evaluation should address not only model performance but also its usability in the clinic.
"I3LUNG establishes a new benchmark for AI in thoracic oncology. Decision support tools built even from routinely available clinical data can outperform the biomarkers we rely on today," Garassino said. "For patients, this means fewer missed opportunities for treatment benefit. For community physicians, it means access to expert-level guidance at the point of care. For the field, it provides a rigorous, fair and explainable framework—validated across diverse health care systems and populations—that can serve as a global platform for the next generation of precision immunotherapy."
Publication details
Arsela Prelaj et al, Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC, Nature Medicine (2026). DOI: 10.1038/s41591-026-04488-2
Journal information: Nature Medicine
Key medical concepts
Clinical categories
Oncology Provided by University of Chicago Medical Center Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: AI tool successfully predicts outcomes of immunotherapy in lung cancer (2026, September 14) retrieved 15 September 2026 from https://medicalxpress.com/news/2026-09-ai-tool-successfully-outcomes-immunotherapy.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.